Data / Form D filings / Sycamore Biopharma, Inc.
Sycamore Biopharma, Inc.: Form D filings
Sycamore Biopharma, Inc., a biotechnology company in West Columbia, SC, filed 2 Form D notices with the SEC between 2019 and 2021. The latest, on March 5, 2021, reports an offering of $175,000 with nothing sold yet.
Find out what Sycamore Biopharma, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 167 Lott Ct., West Columbia, SC, 29169
- Phone
- (803) 206-1290
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- South Carolina
- Year incorporated
- 2018
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1797706
The full lists. Form D filings in South Carolina: 341 rows, $17.05, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 5, 2021 | New notice | $175,000 | $0 | $175,000 | 0 | Yet to occur | sec.gov |
| Dec 20, 2019 | New notice | $500,000 | $500,000 | $0 | 5 | Dec 12, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Chris Sadek | Director | |
| William T. Lamar | Executive Officer, Director | |
| Mark T. Hamann | Executive Officer, Director | |
| R. Tyler Stone III | Executive Officer, Director | |
| H. Lee T. Mashburn, Jr. | Executive Officer, Director |
Every Form D from the week of Mar 1, 2021 · All recent filings in South Carolina · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Sycamore Biopharma, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.